552331-49-4

Basic information

• Product Name: 1-BOC-5-BROMO-INDAZOLE
• Synonyms: N-BOC-5-BROMO INDAZOLE;tert-butyl 5-bromo-3-methyl-1H-indazole-1-carboxylate;5-Bromo-3-methyl-indazole-1-carboxylic acid tert-butyl ester
• CAS NO: 552331-49-4
• Molecular Formula: C12H13BrN2O2
• Molecular Weight: 297.151
• Mol File: 552331-49-4.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 377.4°C at 760 mmHg
• Flash Point: 182°C
• Appearance: /
• Density: 1.46g/cm³
• Vapor Pressure: 6.77E-06mmHg at 25°C
• Refractive Index: 1.599
• PKA: -1.91±0.50(Predicted)
• CAS DataBase Reference: 1-BOC-5-BROMO-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-5-BROMO-INDAZOLE(552331-49-4)
• EPA Substance Registry System: 1-BOC-5-BROMO-INDAZOLE(552331-49-4)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• Hazardous Substances Data: 552331-49-4(Hazardous Substances Data)

Usage

General Description

1-BOC-5-BROMO-INDAZOLE is a chemical compound used in organic synthesis and pharmaceutical research. It is a derivative of indazole, a heterocyclic compound consisting of a five-membered ring containing two nitrogen atoms. The "1-BOC" group refers to the tert-butoxycarbonyl protecting group, which is commonly used in organic chemistry to protect sensitive functional groups during chemical reactions. The presence of the bromine atom on the indazole ring imparts specific properties to the compound, which may be useful in drug development or material science applications. Overall, 1-BOC-5-BROMO-INDAZOLE is a versatile building block with potential applications in various fields of chemistry.

InChI:InChI=1/C12H13BrN2O2/c1-12(2,3)17-11(16)15-10-5-4-9(13)6-8(10)7-14-15/h4-7H,1-3H3

Upstream product

• 552331-16-5 5-bromo-3-methyl-1H-indazole 
• 24424-99-5 di-tert-butyl dicarbonate 
• 198477-89-3 1-(5-bromo-2-fluorophenyl)ethan-1-one 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 
• 552331-15-4 1-(5-bromo-2-fluorophenyl)ethan-1-ol 
• 34619-03-9 tert-butyldicarbonate 

Downstream Products

• 864770-82-1 1,1-dimethylethyl 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-1-carboxylate 
• 267875-55-8 3-methyl-1H-indazole-5-carbonitrile 
• 1015068-77-5 tert-butyl 5-cyano-3-methyl-1H-indazolecarboxylate 

Relevant articles and documents

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer

A novel series of pyridin-3-amine derivatives were designed, synthesized, and evaluated as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC). Hit 1 was first disclosed by in silico screening against fibroblast

FUSED HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF MALARIA

A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein: R1 is -NR3R4 or -OR5; R2 is selected from aryl, heteroaryl, fused aryl- heterocycloalkyl and fused heteroaryl-heterocycloalkyl each of which may be optionally substituted by one or more R8 groups; R3 is H or alkyl; R4 is: (i) cycloalkyl optionally substituted by one or more -NR11R12, -NHCO2R11, -NHCOR11 and -NHSO2R11 groups; or (ii) -(CH2)n-heterocycloalkyl, wherein said heterocycloalkyl is a 4, 5 or 6-membered nitrogen-containing group optionally containing one or more CO groups, wherein said heterocycloalkyl is optionally substituted by one or more one or more (CH2)nR7 groups; (iii) -(CH2)n-heteroaryl, wherein said heteroaryl group is optionally substituted by one or more R7 groups; or (iv) alkyl substituted by one or more -NR11R12groups; or R3 and R4 are linked together with the nitrogen to which they are attached to form a 4, 5 or 6-membered heterocycloalkyl group optionally containing one or two further groups selected from CO, O, N and S, and which is optionally further substituted by one or more R7 groups; R5 is selected from alkyl, -(CH2)n-heteroaryl and -(CH2)n-heterocycloalkyl, wherein said heteroaryl and heterocycloalkyl groups are each optionally substituted by one or more R7 groups; each R11 and R12 is independently H or alkyl; and each n is independently an integer from O to 6; for use in treating or preventing a disorder associated with CDPK. Further aspects relate to the use of said compounds in the treatment of various therapeutic disorders, and more particularly as inhibitors of PfCDPK1.